Global Medical Tech Becton, Dickinson Expects Lower China Sales, Bioscience And Pharma Market Dynamics To Impact 2025 Organic Revenue Growth - Becton Dickinson ( NYSE:BDX )
On Thursday, Becton, Dickinson and Company BDX reported fourth-quarter sales of $5.44 billion, up 6.9% year over year ( +7.4% currency-neutral and 6.2% organic ) , beating the consensus of $5.38 billion.
| Ticker |
Sentiment |
Impact |
|
EW
|
Somewhat Bullish
|
11 %
|
|
BDX
|
Neutral
|
32 %
|
